恩替卡韦治疗 HBeAg 阳性和 HBeAg 阴性慢性乙型肝炎患者的 HBsAg 血清学转换：病例系列。
Seroconversion of HBsAg in HBeAg positive and HBeAg negative patients with chronic HBV treated with entecavir: a case series.
机构信息
Department of Infectious Diseases & Tropical Medicine, Sapienza University, Rome, Italy.
出版信息
Eur Rev Med Pharmacol Sci. 2010 Jun;14(6):551-4.
We report a case series of three HBeAg positive and five HBeAg negative patients (7 males, mean age 50.6 +/- 14.6 years) with chronic HBV infection experiencing seroconversion after treatment with entecavir (0.5 mg/day or 1 mg/day), initiated in 2007. Overall, the mean time to HBsAg clearance was 9.4 +/- 4.5 months. Seroconversion occurred in all patients, after a mean time of 8.0 +/- 3.7 months. In HBeAg negative patients, mean time to HBsAg clearance and to seroconversion were 9.2 +/- 5.9 and 6.8 +/- 4.0 months, respectively. In HBeAg positive patients, mean time to HBsAg clearance and to seroconversion were 9.7 +/- 0.6 months and 10.0 +/- 2.6 months, respectively. In this case series, seroconversion was maintained and was observed both in HBeAg positive patients and in HBeAg negative patients. Therefore, it may be preliminarily suggested that treatment with entecavir could be associated to HBsAg seroconversion in a short period of time, in both HBeAg positive and HBeAg negative HBV patients.
我们报告了三例 HBeAg 阳性和五例 HBeAg 阴性患者（7 名男性，平均年龄 50.6 +/- 14.6 岁）的病例系列，这些患者均患有慢性 HBV 感染，在 2007 年接受恩替卡韦（0.5mg/天或 1mg/天）治疗后发生血清学转换。总体而言，HBsAg 清除的平均时间为 9.4 +/- 4.5 个月。所有患者在平均 8.0 +/- 3.7 个月后均发生血清学转换。在 HBeAg 阴性患者中，HBsAg 清除和血清学转换的平均时间分别为 9.2 +/- 5.9 个月和 6.8 +/- 4.0 个月。在 HBeAg 阳性患者中，HBsAg 清除和血清学转换的平均时间分别为 9.7 +/- 0.6 个月和 10.0 +/- 2.6 个月。在本病例系列中，血清学转换得到维持，并在 HBeAg 阳性和 HBeAg 阴性 HBV 患者中均观察到。因此，初步表明恩替卡韦治疗可能与 HBeAg 阳性和 HBeAg 阴性 HBV 患者在短时间内的 HBsAg 血清学转换有关。
Zotero 插件